Clinical trial NCT01248429: Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases
Official title: National Study of Prevalence of Creatinine Phosphokinase (CPK) Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases (TKI)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cancer
Solid Tumor
Keywords: thyrosine kinase inhibitor
phosphokinase creatinin
myalgia
Lead sponsor: Centre Oscar Lambret
Sponsor class: OTHER
First posted: 2010-11-25
Enrollment: 154
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients treated for a solid tumor by thyrosin kinase inhibitors

Brief summary: This study describes the elevation of CPK in patient treated for solid tumors by TKI


Eligibility criteria: Inclusion Criteria:

* Patients with solid tumor treated by inhibitor of tyrosin kinase for at least 1 week
* Patient examined AND with a routine blood test planned
* Patient informed of procedure for the study who was not opposed to it

Exclusion Criteria:

* Patient treated for malignant hemopathy
* Patient no treated by inhibitor of thyrosine kinase or for less than 1 week
* Patients with no routine blood laboratory tests planned

Primary outcomes:
measure: To evaluate the prevalence of the CPK increase
timeFrame: Within 3 days after a clinical exam
Secondary outcomes:
measure: Correlation myalgia/CPK increase
timeFrame: During the clinical exam
Other outcomes:
Locations:
city: Angers
country: France
facility: Centre Paul Papin
city: Besancon
country: France
facility: Hôpital Jean Minjoz
city: Bordeaux
country: France
facility: CHU Bordeaux
city: Bordeaux
country: France
facility: Institut Bergonié
city: Caen
country: France
facility: Centre François Baclesse
city: Clermont Ferrand
country: France
facility: Centre Jean Perrin
city: Creteil
country: France
facility: Hôpital Henri Mondor - APHP
city: Lille
country: France
facility: Centre Oscar Lambret
city: Limoges
country: France
facility: CHU Limoges
city: Lyon
country: France
facility: Hôpital Edouard Herriot
city: Lyon
country: France
facility: Centre Léon Bérard
city: Marseille
country: France
facility: Institut Paoli Calmettes
city: Montpellier
country: France
facility: Centre Val d'Aurelle
city: Nice
country: France
facility: Centre Antoine Lacassagne
city: Paris
country: France
facility: Hôpital Saint-Louis - APHP
city: Paris
country: France
facility: Hôpital Cochin - APHP
city: Paris
country: France
facility: Hôpital Tenon - APHP
city: Paris
country: France
facility: Institut Curie
city: Reims
country: France
facility: Institut Jean Godinot
city: Reims
country: France
facility: CHU Robert Debré
city: Rennes
country: France
facility: Centre Eugène Marquis
city: Rouen
country: France
facility: Centre Henri Becquerel
city: Saint Cloud
country: France
facility: Centre René Huguenin
city: Saint Priest en Jarez
country: France
facility: Institut de Cancérologie de la Loire
city: Toulouse
country: France
facility: Institut Claudius Régaud
city: Vandoeuvre Les Nancy
country: France
facility: Centre Alexis Vautrin
city: Villejuif
country: France
facility: Institut Gustave Roussy
Study officials:
affiliation: Centre Oscar Lambret
name: Antoine ADENIS, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: